Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review |
| |
| Affiliation: | 2. Department of Hemato-oncology, Saint Joseph University Hospital, Faculty of Medicine, Beirut, Lebanon;3. Department of Ophthalmology, Beirut Eye Specialist Hospital, Beirut, Lebanon;1. Department of Thoracic Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People’s Republic of China;2. Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University, Shenzhen People’s Hospital, Shenzhen, Guangdong, People’s Republic of China;3. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China;4. Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, People’s Republic of China;5. Molecular Diagnosis Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, People’s Republic of China;2. Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas;3. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ontario, Canada;4. Moores Cancer Center, University of California, San Diego, San Diego, California;1. Morsani College of Medicine, University of South Florida, Tampa, FL;2. Department of Radiology, H. Lee Moffitt Cancer Center, Tampa, FL;3. Interventional Pulmonology, H. Lee Moffitt Cancer Center, Tampa, FL;4. Thoracic Oncology Department, H. Lee Moffitt Cancer Center, Tampa, FL |
| |
| Abstract: | ObjectiveTo evaluate the long-term outcomes of intravitreal bevacizumab for peripheral and juxtapapillary retinal capillary hemangioblastoma (RCH).DesignWe conducted a retrospective noncomparative interventional case series.ParticipantsThere were 4 patients (5 eyes) presenting with RCH.MethodsFive eyes with RCH presented with exudative changes and visual loss. Three eyes of 2 patients with peripheral RCH were treated with cryotherapy and 2 intravitreal injections of bevacizumab (0.5 mg). Two eyes with juxtapapillary RCH were treated with 3 intravitreal injections of bevacizumab. The main outcome measures were changes in best-corrected visual acuity (BCVA), lesion size, exudation, and retinal thickness.ResultsIn peripheral RCH, improvement of BCVA from counting fingers to 20/400 was obtained in 1 eye. One patient with bilateral RCH maintained a vision of 20/20 in 1 eye with complete anatomic regression of the 3 small peripheral RCH lesions. The fellow eye with fibrotic bands from the RCH to the optic nerve head developed a tractional retinal detachment after the first injection and was treated with pars plana vitrectomy. In patients with juxtapapillary RCH, bevacizumab injections resulted in an improvement of BCVA from 20/80 to 20/20 in 1 eye, whereas the second eye did not show an improvement of BCVA despite a regression of the tumour.ConclusionsIntravitreal anti–vascular endothelial growth factor agents, alone or in combination with other treatment modalities, may improve visual acuity. Further trials evaluating the dose, the number of injections, and the route of administration will be important in advancing antiangiogenic therapies for RCH. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
